MX2019005194A - Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar. - Google Patents

Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar.

Info

Publication number
MX2019005194A
MX2019005194A MX2019005194A MX2019005194A MX2019005194A MX 2019005194 A MX2019005194 A MX 2019005194A MX 2019005194 A MX2019005194 A MX 2019005194A MX 2019005194 A MX2019005194 A MX 2019005194A MX 2019005194 A MX2019005194 A MX 2019005194A
Authority
MX
Mexico
Prior art keywords
bile acid
combinations
acid sequestrants
fgfr4 inhibitors
fgfr4
Prior art date
Application number
MX2019005194A
Other languages
English (en)
Inventor
Alec Fairhurst Robin
Graus Porta Diana
Joerg Mahl Andreas
Manenti Luigi
Weiss Andreas
Wolf Armin
Wuersch Kuno
Kinyamu-Akunda Jacqueline
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019005194A publication Critical patent/MX2019005194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende un inhibidor de FGFR4 y un secuestrante de ácido biliar, al uso de la combinación farmacéutica en el tratamiento de cáncer, y al uso de un secuestrante de ácido biliar con el fin de reducir o mitigar los efectos secundarios asociados con la terapia de inhibición de FGFR4.
MX2019005194A 2016-11-02 2017-11-01 Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar. MX2019005194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02
PCT/IB2017/056787 WO2018083603A1 (en) 2016-11-02 2017-11-01 Combinations of fgfr4 inhibitors and bile acid sequestrants

Publications (1)

Publication Number Publication Date
MX2019005194A true MX2019005194A (es) 2019-08-05

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005194A MX2019005194A (es) 2016-11-02 2017-11-01 Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar.

Country Status (18)

Country Link
US (1) US11229643B2 (es)
EP (1) EP3534902B1 (es)
JP (2) JP7394623B2 (es)
KR (1) KR102362648B1 (es)
CN (2) CN117257800A (es)
AU (1) AU2017354082B2 (es)
BR (1) BR112019008787A2 (es)
CA (1) CA3042475C (es)
ES (1) ES2934341T3 (es)
IL (1) IL266293B (es)
MA (1) MA46712A (es)
MX (1) MX2019005194A (es)
PL (1) PL3534902T3 (es)
PT (1) PT3534902T (es)
RU (1) RU2742033C2 (es)
SG (1) SG11201903911UA (es)
WO (1) WO2018083603A1 (es)
ZA (1) ZA201902744B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678373B2 (en) 2006-02-10 2010-03-16 Genentech, Inc. Anti-FGF19 antibodies and methods using same
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US9205094B2 (en) * 2006-12-22 2015-12-08 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
AU2008275559B2 (en) 2007-04-02 2014-04-10 Genentech, Inc. Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CA2738034A1 (en) 2008-09-03 2010-03-11 Licentia Ltd. Materials and methods for inhibiting cancer cell invasion related to fgfr4
US20100330175A1 (en) 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
WO2014165287A1 (en) 2013-03-12 2014-10-09 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
CA2902599C (en) 2013-03-15 2023-03-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
TWI597268B (zh) 2013-10-18 2017-09-01 衛材Ｒ＆Ｄ企管股份有限公司 纖維母細胞受體４（ｆｇｆｒ４）抑制劑
SG11201602183QA (en) 2013-10-25 2016-05-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
TW201612518A (en) 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
CA2951153A1 (en) * 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PL3180356T3 (pl) 2014-08-11 2020-04-30 Daiichi Sankyo Europe Gmbh Ludzkie przeciwciało anty-fgfr4
EP3200786B1 (en) * 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
WO2016151501A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
EP3095465A1 (en) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant

Also Published As

Publication number Publication date
KR20190082256A (ko) 2019-07-09
CA3042475A1 (en) 2018-05-11
BR112019008787A2 (pt) 2019-07-16
CN109922804B (zh) 2023-11-17
AU2017354082B2 (en) 2023-07-27
SG11201903911UA (en) 2019-05-30
RU2742033C2 (ru) 2021-02-01
MA46712A (fr) 2019-09-11
US20200261444A1 (en) 2020-08-20
EP3534902A1 (en) 2019-09-11
WO2018083603A1 (en) 2018-05-11
PL3534902T3 (pl) 2023-03-27
EP3534902B1 (en) 2022-11-23
IL266293B (en) 2022-07-01
KR102362648B1 (ko) 2022-02-11
CN109922804A (zh) 2019-06-21
JP2022033766A (ja) 2022-03-02
JP2019533701A (ja) 2019-11-21
CN117257800A (zh) 2023-12-22
RU2019116061A (ru) 2020-12-04
CA3042475C (en) 2024-01-16
RU2019116061A3 (es) 2020-12-04
JP7394623B2 (ja) 2023-12-08
IL266293A (en) 2019-06-30
US11229643B2 (en) 2022-01-25
ZA201902744B (en) 2021-08-25
AU2017354082A1 (en) 2019-05-23
PT3534902T (pt) 2022-12-07
ES2934341T3 (es) 2023-02-21

Similar Documents

Publication Publication Date Title
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
EP4218804A3 (en) Use of myostatin inhibitors and combination therapies
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2019007256A (es) Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12015502091A1 (en) Cdc7 inhibitors
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MA40364A (fr) Polythérapie pour le traitement du cancer
MX2017009246A (es) Farmaco de combinacion.
NZ738389A (en) Inhibitor of igfbp3/tmem219 axis and diabetes
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2021012359A (es) Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
MX2019005194A (es) Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar.
MX2020008923A (es) Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.